TRDA
NASDAQ · Biotechnology
Entrada Therapeutics Inc
$6.87
+0.00 (+0.00%)
Open$7.05
Previous Close$6.87
Day High$7.10
Day Low$6.78
52W High$16.45
52W Low$4.93
Volume—
Avg Volume486.7K
Market Cap267.49M
P/E Ratio—
EPS$-4.00
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+162.6% upside
Current
$6.87
$6.87
Target
$18.04
$18.04
$12.20
$18.04 avg
$27.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 23.93M | 42.90M | 41.05M |
| Net Income | -135,289,341 | 8.98M | 10.98M |
| Profit Margin | -565.5% | 20.9% | 26.8% |
| EBITDA | -144,750,951 | 15.57M | 16.71M |
| Free Cash Flow | — | 11.03M | 8.57M |
| Rev Growth | — | +8.9% | +15.8% |
| Debt/Equity | — | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |